Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.54 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012925 | 0.88 | MAPK14 (0.48) | GRNSORT1NPSR1BRAFGAA | |
| SCHEMBL4465670 | 0.86 | MAPK14 (0.49) | GRNSORT1BRAFRECQLMAPK14 | |
| SCHEMBL1013221 | 0.85 | RAF1 (0.49) | GRNSORT1NPSR1BRAFGAA | |
| SCHEMBL23637699 | 0.83 | MAPK14 (0.53) | GAAMAPK14P2RY14MAPK13MAPK12 | |
| SCHEMBL1010615 | 0.83 | MAPK14 (0.65) | MAPTMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1012412 | 0.82 | MAPK14 (0.60) | BRAFGAACYP2C9CYP2C19MAPK14 | |
| SCHEMBL25488154 | 0.81 | MAPK14 (0.44) | GRNSORT1BRAFRECQLMAPK14 | |
| SCHEMBL19350918 | 0.81 | MAPK14 (0.44) | GRNSORT1NPSR1BRAFRECQL | |
| SCHEMBL4459497 | 0.81 | MAPK14 (0.50) | BRAFGAARECQLMAPK14MAPK13 | |
| SCHEMBL1012616 | 0.80 | MAPK13 (0.66) | GAARECQLMAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| EP-1812433-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| EP-1812433-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006043090-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | GRN 3832/4885SORT1 4001/4885NPSR1 4652/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | GRN 4205/4885SORT1 3415/4885NPSR1 3691/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | GRN 3832/4885SORT1 4001/4885NPSR1 4652/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | GRN 3832/4885SORT1 4001/4885NPSR1 4652/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | GRN 3832/4885SORT1 4001/4885NPSR1 4652/4885 |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | NR2E1, NR0B1, BRAF | GRN 3052/4885SORT1 3571/4885NPSR1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.